publications-banner

Information about pipeline products

PublicationView

Edoxaban
Cardiovascular - AF
Clinical outcomes and anticoagulation therapy in elderly non-valvular atrial fibrillation and heart failure patients
Ikeda S, Hiasa K-I, Inoue H, et al.
ESC Heart Fail. 2024;11(2):902-913.
Edoxaban
Cardiovascular - VTE
Risk factors for bleeding events in Japanese patients with advanced lung cancer: Data from the Rising-VTE/NEJ037 Study
Kawakado K, Tsubata Y, Hotta T, et al.
Cancers. 2024;16(2):301.
Edoxaban
Cardiovascular - VTE
Prevention of symptomatic pulmonary embolism for gynecologic malignancies with preoperative asymptomatic venous thromboembolism: GOTIC-VTE trial
Takahashi Y, Fujiwara H, Yamamoto K, et al.
J Gynecol Oncol. 2024;35(4):e37.
Edoxaban
Cardiovascular - AF
Treatment satisfaction and convenience for patients with atrial fibrillation on edoxaban or vitamin K antagonists after transcatheter aortic valve replacement: A post hoc analysis from the ENVISAGE-TAVI AF trial
Hengstenberg C, Van Mieghem NM, Wang R, et al.
Am J Cardiol. 2023;209:P212-219.
Edoxaban
Cardiovascular - AF Cardiovascular - VTE
Management of edoxaban therapy and clinical outcomes in patients undergoing major or nonmajor surgery: A subanalysis of the EMIT-AF/VTE study
von Heymann C, Unverdorben M, Colonna P, et al.
Thromb J. 2023;21(1):124.
HER3-DXd
Lung Cancer
HERTHENA-Lung02: Phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI
Mok T, Jänne PA, Nishio M, et al.
Future Oncol. 2024;20(15):969-980.
T-DXd
Breast Cancer
Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: Updated survival results from a phase II trial (DESTINY-Breast01)
Saura C, Modi S, Krop I, et al.
Ann Oncol. 2024;35(3):302-307.
Edoxaban
Cardiovascular - AF
Predictors of all-cause mortality after successful transcatheter aortic valve implantation in patients with atrial fibrillation
Yamamoto M, Hayashida K, Hengstenberg C, et al.
Am J Cardiol. 2023;207:P150-158.
T-DXd
Gastric Cancer
Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study
Shitara K, Yamaguchi K, Muro K, et al.
Int J Clin Oncol. 2024;29(1):27-35.
Edoxaban
Cardiovascular - VTE
A multicenter, single-blind, randomized, warfarin-controlled trial of edoxaban in patients with chronic thromboembolic pulmonary hypertension: KABUKI trial
Hosokawa K, Watanabe H, Taniguchi Y, et al.
Circulation. 2024;149(5):406-409.
Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  

footer